Mountain View, California (February 6, 2012) – Singularity University (SU), the only educational institution uniquely focused on the impact and opportunities presented by exponentially advancing technologies, has announced a new high-level partnership with Genentech, one of the world’s leading biotechnology companies. The announcement was made on the opening day of Exponential Medicine, a signature SU program which explores the future of medicine through rapidly developing, disruptive, and convergent technologies and how they are poised to revolutionize healthcare.
Genentech will join Singularity University Founding Partners Autodesk, Cisco, Google, the Kauffman Foundation, Nokia, and ePlanet Ventures at the highest level of sponsorship, in addition to becoming a Platinum Sponsor of the 2012 Exponential Medicine Program at Singularity University. Exponential Medicine runs from February 6-11 on the SU campus at NASA Research Park at Moffett Field, California.
“We are very excited to welcome Genentech to Singularity University as our first large-scale biotech partner,” said Rob Nail, CEO of Singularity University. “It’s a tremendous opportunity to be partnered with a company so committed to cutting edge science, innovation, and improving medicine and healthcare.”
The new partnership between Singularity University and Genentech will also support the annual SU Summer Global Solutions Program, a 10-week graduate-level interdisciplinary curriculum designed to facilitate innovation across a broad range of scientific and technological disciplines whose developments are accelerating exponentially. The keystone of the program, the Ten to the Ninth Plus (10^9+) Team Projects, challenge students to develop services, products, companies and organizations that have the ability to positively affect the lives of one billion people within 10 years.
About Genentech (www.gene.com)
Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. Their current portfolio of pharmaceuticals includes therapies in Oncology, Immunology, and Infectious Disease. Genentech is also acknowledged for their commitment for Access To Care initiatives. Approximately $2.3 billion in free medicine has been donated through the Genentech Access To Care Foundation (GATCF) for at-risk and underinsured patients.
About Exponential Medicine (exponential.singularityu.org/medicine)
Exponential Medicine is a unique multidisciplinary and immersive hands-on experience, uniquely designed for healthcare professionals and those interested in medical related innovation. The week-long program educates and prepares physicians, senior health care executives, entrepreneurs and investors to understand and recognize the opportunities and disruptive influences of exponential and rapidly developing technologies. The implications of these technologies are poised to revolutionize medicine, healthcare, and the biotechnology industry in the decade ahead. Core tracks include Information/Data-driven and Internet enabled health care, Genomics and Personalized Medicine, Regenerative Medicine, Robotics & Future Interventional approaches, NeuroMedicine, Device & Drug development, and Entrepreneurship.
About Singularity University (www.singularityu.org)
Singularity University’s mission is to assemble, educate, and inspire a new generation of leaders in business, science, finance, and government who strive to understand and utilize exponentially advancing technologies to address humanity’s grand challenges. Since it was established in 2009, Singularity University has hosted students and industry leaders from 40 countries at its campus at NASA Research Park in California.
Singularity University offers both graduate studies and executive programs focused on the impact and incubation of exponentially growing technologies in six key areas: medicine and neuroscience, networks and computing systems, artificial intelligence and robotics, biotechnology/bioinformatics, nanotechnology, and energy and environmental systems.